
The RELIGHT study found that adding retlirafusp alfa to chemotherapy extended overall and progression-free survival in previously untreated gastric and GEJ cancers.
Daniel Catenacci, MD, reviews the case of a 71-year-old man with gastric cancer.
Case: A 71-Year-Old Man With HER2+ Gastric Cancer
Initial Presentation
Clinical Workup
Treatment